A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

199

Participants

Timeline

Start Date

April 21, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Tobemstomig

Participants will receive IV tobemstomig Q3W.

DRUG

Tiragolumab

Participants will receive IV tiragolumab Q3W.

DRUG

Pembrolizumab

Participants will receive IV pembrolizumab Q3W.

DRUG

Axitinib

Participants will receive axitinib PO BID.

Trial Locations (44)

4575

Sunshine Coast University Hospital, Birtinya

10408

National Cancer Center, Goyang-si

14004

Hospital Universitario Reina Sofia, Córdoba

14076

Centre Francois Baclesse, Caen

20016

Sibley Memorial Hospital, Washington D.C.

20246

Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II, Hamburg

21287

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

25030

CHU Besançon - Hôpital Jean Minjoz, Besançon

28034

Hospital Universitario Ramon y Cajal, Madrid

28040

Hospital Universitario Clínico San Carlos, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

30322

Emory University, Atlanta

30625

Medizinische Hochschule Hannover, Hanover

33075

CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre, Bordeaux

35294

University of Alabama at Birmingham, Birmingham

37203

SCRI Oncology Partners, Nashville

37232

Vanderbilt University Medical Center, Nashville

41013

Hospital Universitario Virgen del Rocio, Seville

46026

Hospital Universitari i Politecnic La Fe, Valencia

58128

Chonnam National University Hwasun Hospital, Jeollanam-do

69373

Centre Leon Berard, Lyon

72622

Studienpraxis Urologie, Nürtingen

81675

Klinikum rechts der Isar der TU München, München

84918

Institut Sainte Catherine, Avignon

89081

Universitätsklinikum Ulm, Ulm

92868

UC Irvine Medical Center, Orange

94800

Institut Gustave Roussy, Villejuif

100034

Peking University First Hospital, Beijing

100142

Beijing Cancer Hospital, Beijing

210008

Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing

300060

Tianjin Cancer Hospital, Tianjin

75390-9179

UT Southwestern Medical Center, Dallas

01307

"Universitätsklinikum Carl Gustav Carus", Dresden

36-200

Szpital Specjalistyczny Podkarpacki O?rodek Onkologiczny, Brzozów

85-796

Centrum Onkologii im. Prof. Franciszka ?ukaszczyka, Bydgoszcz

31-501

Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii, Krakow

60-569

Szpital Kliniczny im. Heliodora ?wi?cickiego UM w Poznaniu, Późna

03722

Severance Hospital, Yonsei University Health System, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

08025

Hospital de la Santa Creu i Sant Pau, Barcelona

08035

Hospital Universitari Vall d'Hebron, Barcelona

EC1A 7BE

Barts & London School of Med, London

M2O 4BX

Christie Hospital Nhs Trust, Manchester

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY